April 8, 2021
Teijin Pharma President Ichiro Watanabe Teijin Pharma is set to rev up the transformation of its pharmaceuticals and medical devices business revolving around diabetes by leveraging the acquisition of four DPP-4 inhibitor products from Takeda Pharmaceutical, which was just completed...read more